Pure EPA Vascepa® (icosapent Ethyl) Showed Reductions In Potentially Atherogenic Lipid And Inflammatory Parameters In Statin-Treated Women With Persistent High Triglycerides

BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced an oral presentation at the American Heart Association Scientific Sessions 2016, New Orleans on November 14, 2016 that further characterized the efficacy and safety of Vascepa® (icosapent ethyl) in statin-treated women with persistent high triglyceride levels.

The presentation of additional data from the ANCHOR study showed, consistent with overall study results, that prescription pure EPA Vascepa® (icosapent ethyl) reduced triglyceride levels and several other potentially atherogenic lipid parameters and inflammatory markers in a subgroup of statin-treated women with persistent high triglycerides. The post hoc analysis supporting the efficacy of pure, prescription icosapent ethyl in this patient population was presented as an oral abstract (#309) titled, "Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Statin-Treated Women With Persistent High Triglycerides: Results From the ANCHOR Study."

The analysis is published in the American Journal of Cardiology; an early version of the manuscript is accessible at http://www.ajconline.org/article/S0002-9149(16)31738-6/pdf.

The analysis was led by Lori Mosca, MD, MPH, PhD, Professor of Medicine Emerita and Center Director of the American Heart Association Go Red for Women Research Network at Columbia University Medical Center, New York.  Researchers observed that compared to placebo, Vascepa administered at 4 g/day significantly reduced triglycerides (TGs) without increasing LDL ("bad") cholesterol in women from the ANCHOR study with TG levels between 200 to 499 mg/dL.  In addition, statistically significant improvements were observed in numerous potentially atherogenic parameters (lipids and lipoproteins) and inflammatory markers.

"It is important to generate data that address the specific needs of women, especially in fields where the data could prove useful to patient care," said Dr. Mosca. "While further study is needed and ongoing, this analysis is encouraging because the efficacy and safety of Vascepa 4 g/day in this subgroup of 91 statin-treated women with persistent high triglycerides were consistent with the overall ANCHOR results, which included 702 patients.  It is vitally important to evaluate both potential benefits and side effects of therapies in women and not assume results from men are similar in women."

If you liked this article you might like

Biotech Premarket Movers: Cempra, Novavax, Ionis

Amarin (AMRN) Stock Drops After Pricing Public Offering

Tetraphase Executive Profits Hours Before Stock Plummets

5 Stocks Ready for Breakouts -- Must-See Charts

3 Stocks Under $10 Making Big Moves